💸 The Tape

Virginia's Cannabis Control Authority released its first draft of adult-use regulations on September 9, and the document does two things at once. It builds the licensing architecture for a market that opens July 1, 2027, and it quietly cements the advantage of the five companies already growing cannabis in the Commonwealth. If the rules go into effect as written, the launch belongs to the medical operators. The question is how long that lasts.

What the draft actually establishes

The retail ceiling is 350 licensed stores. Cultivation is split into five tiers, and the draft fills in only the top one: five Tier V licenses, with the counts for Tiers I through IV and processing facilities left as literal placeholders. That's the most telling detail in the package. The CCA has settled the shape of the retail market but not the supply side, which means the fight over how much canopy Virginia will allow is still being waged.

The rest is procedural but consequential. Applicants get 18 months from preliminary approval to open, with a 1,000-foot buffer from schools and daycares. Awards go by lottery when qualified applicants exceed available licenses. Impact licensees can't sell a controlling stake for five years. Wholesale distribution between licensees is permitted, including of untested product between processors. Fees are moderate by limited-license standards: $50,000 to authorize a Tier V grow, $20,000 for a retail store, $2,500 for a microbusiness. Adult-use retailers are barred from drive-thru, curbside and vending; medical facilities keep their drive-thru windows for pre-orders.

The operators already on the ground

Virginia's medical program was designed as five regional monopolies, one vertically integrated pharmaceutical processor per health service area, each allowed up to six retail locations. That map has consolidated hard in the past two years. Jushi holds HSA II, Northern Virginia, the most populous and affluent region in the state, with its Beyond Hello stores. Green Thumb runs HSA III in Southwest Virginia under RISE. Verano bought HSA V — Hampton Roads, roughly two million residents and heavy tourist traffic — from Cannabist for $90 million in 2024. And Arboretum Virginia, a vehicle backed by Boston's Millstreet Capital, now controls two regions: it paid $130 million for Cannabist's Richmond business in HSA IV this February and picked up Ayr's long-vacant HSA I permit in the Shenandoah Valley.

So the incumbent roster is three public MSOs and one credit fund, sitting on roughly 30 dispensaries and five cultivation campuses in a state of 8.7 million people that has never had a legal adult-use store.

How the HSAs are treated differently

The draft doesn't say "medical operators go first." It doesn't have to. The structural advantages are built into the definitions.

First, the dual-use pathway. Existing processors and their dispensing facilities can be authorized to exercise adult-use privileges from their current locations, under their current permits, with a pharmacist still on site. Under the enabling statute, they have until November 1 to apply and pay for that privilege. A new entrant, by contrast, applies into a lottery, waits for preliminary approval, then has 18 months to build. The incumbents are selling adult-use on July 1, 2027 from facilities that already exist; the first new-entrant stores realistically open in 2028.

Second, supply. The draft explicitly allows wholesale distribution between establishments, and each processor can seek one additional cultivation location. With Tier I–IV cultivation counts still blank and every new grow facing an 18-month build, the only flower in the state at launch comes from five campuses. Jushi, Green Thumb, Verano and Arboretum aren't just retailers on opening day — they're the entire wholesale market, selling to whatever microbusinesses and impact licensees manage to open. Minnesota just ran this exact experiment, and Green Thumb's wholesale margins there tell you how it ends.

Third, geography. The 350-store cap will be distributed across the state, but the incumbents already sit in the best trade areas of every region with permitted, zoned, secured buildings. The 1,000-foot school buffer and local approval process that new entrants must clear are hurdles the HSAs cleared years ago.

Fourth, the drive-thru carve-out. Medical facilities keep pre-order drive-thru windows; adult-use stores don't get them at all. It's a small operational edge that compounds in suburban Northern Virginia, where Jushi's stores are.

What it means if this goes live on schedule

For the incumbents, Virginia becomes one of the most attractive limited-license adult-use states in the country: a 350-store cap in a large, wealthy population, a launch window where four companies control supply, and a tax structure. Green Thumb and Verano get a clean growth market at a moment when their core states are saturating. Arboretum gets a payoff on $130 million-plus of very well-timed buying.

For Jushi, HSA II is the single most valuable asset on a balance sheet that badly needs one. Northern Virginia at launch, with adult-use privileges and wholesale rights, is the kind of license that gets bought at a strategic multiple — and it's why any conversation about Jushi as a target starts in Virginia, not Pennsylvania.

For new entrants and the impact program, the draft is a warning. The blank tier counts mean supply policy is undecided, the lottery means capital doesn't buy certainty, the five-year transfer lock keeps impact licensees from flipping, and the 18-month clock starts before most will have a landlord. The first two years of Virginia's adult-use market will be an incumbent market with a social equity program attached, and the draft rules make that outcome more likely, not less.

The caveats

This is a draft, and the CCA is already behind its statutory calendar, which called for final rules by September 1. Arboretum still has to prove out HSA I, which sat vacant for five years. Spanberger and the General Assembly spent the spring fighting over launch dates, and a market that slips from July 2027 to 2028 changes every operator's math. And the blanks in the cultivation section could be filled in either direction — a generous canopy count would compress the incumbent supply advantage quickly.

But if the document becomes law roughly as written and the July 1 date holds, Virginia's adult-use launch will look a lot like its medical program: five regions, five operators, and everyone else in line.

📈 Dog Walkers

NuggMD Poll: You’ve Got Mail

Georgia may be the first state to put medical cannabis in the mailbox, and consumers are already sold on the idea. The latest The Dales Report x NuggMD Cannabis Consumer Poll, fielded August 27 through 31 with 596 respondents and a ±4.01% margin of error, asked a simple question: if medical cannabis could be mailed straight to your door, would that change how you shop?

55 percent said yes. The bigger share, 31.4 percent, said there isn't a dispensary within a reasonable distance of where they live. Another 23.8 percent said a local dispensary exists, but health or mobility issues make getting there a real problem. In other words, the demand isn't about convenience. It's about access for patients the current retail model quietly leaves out.

The holdouts are a smaller crowd. 16.8 percent prefer buying in person, and just 7 percent cited privacy or security concerns about receiving cannabis by mail. A meaningful 21 percent are undecided and want details on cost, packaging, and delivery time before committing, which is a reasonable ask for a service that doesn't exist yet.

The finding lines up with NuggMD's earlier data. A February 2025 poll found 55 percent were highly interested in home delivery via app or online. A May 2025 survey showed only 12 percent rank dispensary location as their top priority, well behind product selection and price. And a late-2024 poll found most consumers shop when they're running low or when products go on sale, both of which lend themselves to scheduled or advance ordering.

Tyler Elson, NuggMD's Director of Content, put it plainly: legal medical cannabis doesn't guarantee accessible medical cannabis. With federal rescheduling opening the door to USPS delivery, Georgia officials are looking at a barrier most states have never bothered to address. If the numbers hold, they'd be giving thousands of qualified patients a path to medicine their doctors already recommended.

$IXHL ( ▼ 4.15% ) Update

Incannex Healthcare (Nasdaq: IXHL) dropped a corporate update Wednesday that reads like a checklist for what a clinical-stage biotech is supposed to look like when things are going right: patients dosed, patent granted, cash in the bank, no debt.

The headline item is DReAMzz, the company's Phase 2 crossover dose-optimization study of IHL-42X in obstructive sleep apnea. First patient dosing kicked off in late August across 13 U.S. sites, all with IRB sign-off. The protocol was built with the company's sleep medicine advisory board and reviewed by the FDA, with agency feedback folded into the final design. The goal is straightforward: nail down dosing so the company can walk into a Phase 3 registration program with confidence.

IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, hitting two different physiological levers in OSA. The earlier RePOSA trial (121 subjects, 16 sites) showed statistically significant reductions in apnea-hypopnea index and oxygen desaturation index versus placebo, with individual AHI reductions reaching 83 percent. The FDA handed it Fast Track designation in December 2025.

On the IP front, the USPTO granted a composition and methods-of-treatment patent on June 25 with a baseline expiry of July 2040, and Incannex is already evaluating patent term extension should approval arrive.

The psychedelics program isn't idle either. PSX-001, the company's synthetic psilocybin candidate for generalized anxiety disorder, has positive Phase 2 data from the 73-subject PsiGAD1 study, an open U.S. IND for a Phase 2b dose-comparison trial, and a scientific advice meeting under its belt with the UK's MHRA.

Then the balance sheet: roughly $70 million in cash, zero debt, and more than A$11.2 million in non-dilutive capital collected this year through Australia's R&D tax incentive program.

CEO Joel Latham summed it up as a program that's "well protected" and "well funded." For a sector where dilution is usually the default financing plan, that combination stands out.

📺 Trade To Black

Where the Hemp and Cannabis Industry Really Stand Right Now | TTB Presented by Flowhub

• Flowhub CEO Kyle Sherman breaks down Labor Day 2026 sales data: just a ~5% lift over a normal weekend, flat cart sizes, and no breakout day, versus 4/20's 3.3x revenue spike. His takeaway for retailers heading into Green Wednesday and Black Friday: not every holiday deserves the same deep discounts.

• Brian Dombrowski, a 20+ year hemp and cannabis veteran and longtime TDR viewer, joins on camera to lay out what real hemp regulation should look like as the December 11 federal deadline approaches.

• Dombrowski also goes inside the Texas THC ban fight, where he was directly involved in the industry pushback, and what the state's midterms could mean next.